Genhui Chen

Welichem Biotech, Inc. operates as a drug discovery and early stage drug development company focusing on novel therapeutics for autoimmune, inflammatory diseases and cancers. The firm's focus has been on research and development of its novel anti-inflammatory drug candidate, WBI-1001 and its derivatives, and its anticancer drug candidate, WBI-2100 and its derivatives. The company was founded on November 1, 2004 and is headquartered in Burnaby, Canada.

Lianluo Smart Ltd. engages in the development and marketing of medical wearable devices, smart devices and ecosystem platform. The medical wearable sector focuses on wearable sleep respiratory devices, focusing primarily on sleep respiratory solutions to obstructive sleep apnea syndrome. The smart devices sector is specialized in operating easy-use smart devices for sports, social contact, entertainment, remote-control and family health management, which can connect things and humans in an intelligent way. The smart ecosystem platform sector, intends to build an ecosystem to facilitate interconnection among smart products and between smart products and users. The company was founded by Ping Chen on July 22, 2003 and is headquartered in Beijing, China.